FDA Announces Crackdown on Non-Approved GLP-1 Drug Compounds
The U.S. Food and Drug Administration announced its intent to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs that are being mass-marketed by companies, targeting the growing market of compounded weight loss medications.